Emergent BioSolutions news from FierceBiotech
NewsEmergent adds new space for biotech start-ups
Emergent Technologies Inc has doubled its office space, taking new digs in Austin that includes new laboratory space for the biotech companies that it helps foster. ETI specializes in creating new Read more...
Emergent BioSolutions buys flu vaccine maker
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug Read more...
Struggling VaxGen sells anthrax vaccine to rival
After spending $175 million in an unsuccessful effort to push a new anthrax vaccine into the clinic, VaxGen has sold the program to Emergent BioSolutions for $2 million. VaxGen also stands to earn Read more...
ALSO NOTED: Minnesota hands out research cash; BMS, Lundbeck execs jump ship; and much more...
> The Minnesota Partnership for Biotechnology and Medical Genomics is handing out $6 million to seven teams that will research heart disease, mesothelioma, infection prevention and epilepsy. Read more...
ALSO NOTED: GSK losing its grip on HIV market; Ranexa gets angina review; Start-up CRO takes flight;and much more...
> Watch out, GlaxoSmithKline. The market for HIV drugs may be expanding, but it's shifting like the San Andreas Fault at the same time, and more than a handful of companies are poised to challenge Read more...
ALSO NOTED: MS drug enters Phase III; Undaunted by data, Northfield looks to FDA; Sonus looks ahead; and much more...
> Genzyme and Bayer have launched their first Phase III trial of alemtuzumab for MS. Read more...
| Press ReleasesPRESS RELEASE: HHS Remains Committed to Procurement of BioThrax Under Current Contract U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax Under Current Contract ROCKVILLE, Md. -- Nov. 19, 2007--Emergent BioSolutions Inc. (NYSE:EBS) announced Read more... PRESS RELEASE: Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Emergent BioSolutions, announced today that it has signed a three year contract with the Read more... |
Get more Emergent BioSolutions coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends